v3.25.1
REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Total net revenues $ 197,122 $ 137,430
Rare Disease and Brands total net revenues    
Disaggregation of Revenue [Line Items]    
Total net revenues 94,082 62,616
Rare Disease total net revenues    
Disaggregation of Revenue [Line Items]    
Total net revenues 68,959 36,937
Cortrophin Gel    
Disaggregation of Revenue [Line Items]    
Total net revenues 52,850 36,937
ILUVIEN and YUTIQ    
Disaggregation of Revenue [Line Items]    
Total net revenues 16,109 0
Brands    
Disaggregation of Revenue [Line Items]    
Total net revenues 25,123 25,679
Generics and Other total net revenues    
Disaggregation of Revenue [Line Items]    
Total net revenues 103,040 74,814
Generic pharmaceutical products    
Disaggregation of Revenue [Line Items]    
Total net revenues 98,678 70,217
Royalties and other pharmaceutical services    
Disaggregation of Revenue [Line Items]    
Total net revenues $ 4,362 $ 4,597